← boardnext 2027-05next 2027-07-07
KLRA
Kaileradistress 2/10 · well-funded / low risk$17.64-1%today-32% from 52w high
Metabolic / Obesity 1
Lead: Obesity · est. market ~$15B (approx, global)
Revenue
pre-revenue
Liquidity
$582M
Runway
2.1 yrs
Shares 1y
—
Price & events
-32.2% over 6M
CatalystRating changeDilutionFinancingdashed = today
-0.8%
1D
-3.7%
1W
-17.5%
1M
-29.7%
3M
—
6M
—
1Y
—
2Y
—
5Y
-32.2%
All
Overview
- Market Cap
- $2.29B
- Volume
- 55.56K
- 52 Week Range
- $17.64 – $26.00
- Total Shares
- 129.57M
- Float Shares
- 58.40M
- Short %
- 3.93%
- % Held by Insiders
- 0.00%
- % Held by Institutions
- 44.94%
- RVOL
- 0.06x
Pipeline stages · 2 programs
Ribupatide
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
KAI-9531
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 7 trials · 5 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2027-05 Estimated 50% readout ~2027-06-15 | Phase 2 | Ribupatide | Obesity | — | enrolling by invitation |
| 2027-07-07 Estimated 50% readout ~2027-08-21 | Phase 2 | KAI-7535 | Obesity, Overweight | — | recruiting |
| 2028-02-28 Estimated 50% readout ~2028-05-13 | Phase 3 | KAI-9531 | Obesity, Overweight | — | recruiting |
| 2028-03-20 Estimated 50% readout ~2028-06-03 | Phase 3 | KAI-9531, Semaglutide | Obesity | — | recruiting |
| 2028-03-27 Estimated 50% readout ~2028-06-10 | Phase 3 | KAI-9531 | Obesity With Diabetes, Overweight With Diabetes | — | recruiting |
Catalyst news & presentations · 1
- 2026-08-12Estimated 45%earningsEarningsEarnings releaseyahoo
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $43 (+141% upside) · 5 analysts
- 2026-05-12Leerink PartnersOutperform
- 2026-05-12JefferiesBuy
- 2026-05-12Evercore ISI GroupOutperform
- 2026-05-12JP MorganOverweight
Competitors — Obesity
- LLYELI LILLY & Co$1094.4B · D3
- AMGNAMGEN INC$195.4B · D3
- GPCRStructure Therapeutics Inc.$11.2B · D4
- RYTMRHYTHM PHARMACEUTICALS, INC.$7.0B · D0
- MBXMBX Biosciences, Inc.$2.8B · D2
- WVEWave Life Sciences Ltd.$1.1B · D1
- CRBPCorbus Pharmaceuticals Holdings, Inc.$164M · D7
- GUTSFRACTYL HEALTH, INC.$123M · D9
- MTVAMetaVia Inc.$8M · D7
- NONOFNOVO NORDISK A S— · D2
Recent news
- 2026-07-21Parabilis tops Kailera as biopharma IPOs surge to best H1 since 2021 - BioWorld News
- 2026-07-20PJT Partners Inc. to Report Second Quarter and Six Months 2026 Financial Results and Host a Conference Call on July 28, 2026 - Business Wire
- 2026-07-20Paymentus to Report Second Quarter 2026 Earnings Results and Host Webcast on August 3, 2026 - Business Wire
- 2026-07-20Top Kailera Therapeutics (KLRA) Competitors 2026 - MarketBeat
- 2026-07-20Kailera Therapeutics (KLRA) Stock Price, News & Analysis $KLRA - MarketBeat
- 2026-07-16Kailera Therapeutics, Inc. (NASDAQ:KLRA) Short Interest Up 96.0% in June - MarketBeat
- 2026-07-16Kailera Therapeutics (NASDAQ:KLRA) Hits New 52-Week Low - What's Next? - MarketBeat
- 2026-07-16PJT Partners Inc. Announces Chief Financial Officer Transition - Business Wire
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.